YOUR FIRST CHOICE IN
RESISTANCE DETECTION
MicroScan Gram Negative Conventional Panels
Abbr.
Panel Name
Neg
Combo 31
Neg
Combo 32
Neg
Combo 44
Neg
Combo 50
Neg
Combo 67
Neg
Combo 68
Neg BP
Combo 30
Neg BP
Combo 34
Neg BP
Combo 41
Neg BP
Combo 44
Neg BP
Combo 47
Neg/Urine
Combo 33
Neg/Urine
Combo 35
Catalog Number
B1017–301
B1017–302
B1017–401
B1017–406
B1017–421
B1017–422
B1017–306
B1017–404
B1017–408
B1017–411
B1017–417
B1017–303
B1017–305
Languages
E, ES, PT
E, ES, PT
E, ES, FR,
PL, PT, RU
E, ES, FR,
PL, PT
E, ES,
FR, PT
E, ES,
FR, PT
DE, E, ES,
FR, PL, PT
E, ES, FR,
PL, PT, RU
E, ES, FR,
PL, PT
E, ES, FR,
PL, PT
E, ES, FR,
PT, RU
E, ES, PT
E, ES, PT
Antimicrobic Agent
µg/mL
µg/mL
µg/mL
µg/mL
µg/mL
µg/mL
µg/mL
µg/mL
µg/mL
µg/mL
µg/mL
µg/mL
µg/mL
Ak
Amikacin
16 – 32
4 – 32
4 – 32
8 – 32
8 – 32
16 – 32
16 – 32
16 – 32
16 – 32
16 – 32
16 – 32
16 – 32
8 – 32
Aug
Amoxicillin/K Clavulanate
8/4 – 16/8
–
–
8/4 – 16/8
–
8/4 – 16/8
8/4 – 16/8
8/4 – 16/8
8/4 – 16/8
8/4 – 16/8
8/4 – 16/8
8/4 – 16/8
8/4 – 16/8
Am
Ampicillin
8 – 16
8 – 16
8 – 16
8 – 16
4 – 16
8 – 16
8 – 16
8 – 16
8 – 16
8 – 16
8 – 16
2 – 16
2 – 16
A/S
Ampicillin/Sulbactam
8/4 – 16/8
8/4 – 16/8
8/4 – 16/8
–
4/2 – 16/8
8/4 – 16/8
8/4 – 16/8
8/4 – 16/8
8/4 – 16/8
8/4 – 16/8
8/4 – 16/8
8/4 – 16/8
8/4 – 16/8
Azt
Aztreonam
8 – 16
8 – 16
8 – 16
8 – 16
4 – 16
–
8 – 16
8 – 16
8 – 16
8 – 16
8 – 16
8 – 16
–
Cfz
Cefazolin
2 – 16
4 – 16
4 – 16
8 – 16
4 – 16
2 –4
8 – 16
8 – 16
8 – 16
8 – 16
8 – 16
8 – 16
8 – 16
Cpe
Cefepime
2 – 16
2 – 16
2 – 16
8 – 16
1 – 16
4 – 16
8 – 16
8 – 16
8 – 16
8 – 16
8 – 16
8 – 16
8 – 16
Cft
Cefotaxime1
4 – 32
4 – 32
2, 8 – 321
2, 8 – 321
2, 161
2, 8 – 321
8, 32
2, 8 – 321
2, 8 – 321
2, 8 – 321
2, 8 – 321
8, 32
4 – 8, 32
Cft/CA
ESβL ConfirmationCefotaxime/K Clavulanate
–
–
0.5/4, 4/4
0.5/4, 4/4
0.5/4, 4/4
0.5/4, 4/4
–
0.5/4, 4/4
0.5/4, 4/4
0.5/4, 4/4
0.5/4, 4/4
–
–
Ctn
Cefotetan
–
16 – 32
16 – 32
–
–
–
16 – 32
16 – 32
–
–
–
–
–
Cfx
Cefoxitin
8 – 16
–
–
8 – 16
–
–
8 – 16
8 – 16
8 – 16
8 – 16
8 – 16
–
–
Cpd
Cefpodoxime
–
–
–
–
–
–
–
–
–
–
–
–
–
Caz
Ceftazidime1
2 – 16
2 – 16
1, 4 – 161
1, 4 – 161
1, 81
1, 4 – 161
8-16
1, 4 – 161
1, 4 – 161
1, 4 – 161
1, 4 – 161
2 – 16
2 – 16
Caz/
CA
ESβL ConfirmationCeftazidime/K Clavulanate
–
–
0.25/4, 2/4
0.25/4, 2/4
0.25/4, 2/4
0.25/4, 2/4
–
0.25/4, 2/4
0.25/4, 2/4
0.25/4, 2/4
0.25/4, 2/4
–
–
Cax
Ceftriaxone
4 – 32
8, 32
8, 32
8 – 32
1– 8
1– 2, 8, 32
8, 32
8, 32
8, 32
8, 32
8, 32
8 – 32
4 – 32
Crm
Cefuroxime
–
4 – 16
4 – 16
4 – 16
4 – 16
4 – 16
4 – 16
4 – 16
4 – 16
4 – 16
4 – 16
4 – 16
4 – 16
Cf
Cephalothin
–
–
–
–
–
–
8 – 16
8 – 16
8 – 16
8 – 16
–
8 – 16
8 – 16
C
Chloramphenicol
–
–
–
–
–
–
8 – 16
–
–
–
–
–
–
Cp
Ciprofloxacin
1 –2
1– 2
1– 2
1– 2
0.5 – 2
1– 2
1– 2
1– 2
1– 2
1– 2
1– 2
1– 2
1– 2
Dor
Doripenem
–
–
–
–
–
–
−
−
−
−
0.5 – 2
–
–
Etp
Ertapenem
–
–
–
2 –4
0.5 – 1
0.5 – 2
–
2 –4
2 –4
1-4
1– 4
–
–
ESβL
ESβL Screen
a, b
a, b
–
–
–
–
a, b
–
–
–
–
a, b
a, b
Gat
Gatifloxacin
2 –4
–
–
–
–
–
2 –4
–
–
–
–
2 –4
–
Gm
Gentamicin
1– 8
1– 8
1– 8
4 –8
2 –8
2 –8
4 –8
4 –8
4 –8
4 –8
4 –8
1– 8
1– 8
Imp
Imipenem
4 –8
4 –8
4 –8
1– 8
–
1– 8
4 –8
4 –8
4 –8
4 –8
1– 8
4 –8
4 –8
Lvx
Levofloxacin
2 –4
2 –4
2 –4
2 –4
1– 4
2 –4
2 –4
2 –4
2 –4
2 –4
2 –4
2 –4
2 –4
–
Mer
Meropenem
–
4 –8
4 –8
1– 8
1– 8
1– 8
4 –8
4 –8
4 –8
4 –8
–
–
Mxf
Moxifloxacin
–
2 –4
2 –4
–
–
–
2 –4
2 –4
2 –4
–
–
–
–
Fd
Nitrofurantoin
–
–
–
–
–
–
32 – 64
32 – 64
32 – 64
32 – 64
32 – 64
32 – 64
32 – 64
Nxn
Norfloxacin
–
–
–
–
–
–
4 –8
–
–
–
–
–
4 –8
Pi
Piperacillin
16, 64
16, 64
–
16, 64
–
–
16, 64
–
16, 64
16 – 64
–
8 – 64
16, 64
P/T
Piperacillin/Tazobactam
8 – 64
8 – 16, 64
8 – 16, 64
16, 64
16 – 64
16 – 64
16, 64
16, 64
16, 64
16, 64
16 – 64
16, 64
8 – 64
Te
Tetracycline
–
–
–
4 –8
2 –8
4 –8
4 –8
4 –8
4 –8
4 –8
4 –8
4 –8
4 –8
Tim
Ticarcillin/K Clavulanate
16 – 64
16, 64
16, 64
16, 64
–
–
16, 64
16, 64
16, 64
–
–
16, 64
16, 64
Tgc
Tigecycline
–
–
–
–
–
2 –4
–
–
–
2 –4
2 –4
–
–
To
Tobramycin
1– 8
1– 8
1– 8
4 –8
2 –8
4 –8
4 –8
4 –8
4 –8
4 –8
4 –8
1 –8
2 –8
T
Trimethoprim
–
–
–
–
–
–
–
–
–
–
–
8
–
T/S
Trimethoprim/
Sulfamethoxazole
2/38
2/38
2/38
2/38
2/38
2/38
2/38
2/38
2/38
2/38
2/38
2/38
0.5/9.5,
2/38
21
22
21
25
21
23
30
27
27
26
24
25
23
Total Antimicrobics/Panel
ESβL a = Cefpodoxime 4µg/ml
ESβL b = Ceftazidime 1µg/ml
1. ESβL Confirmation dilutions:
Cefotaxime 2, 16
Ceftazidime 1, 8
All antibiotics on these panels are cleared for antimicrobial susceptibility testing by the
U.S. Food and Drug Administration.
Neg/Urine
Combo 46
Neg/Urine
Combo 51
Neg/Urine
Combo 55
Neg/Urine
Combo 60
Neg/Urine
Combo 61
Neg/Urine
Combo 62
Neg/Urine
Combo 73
Neg
MIC 38
Neg
MIC 42
Neg
MIC 43
ESβL plus
B1017–403
B1017–407
B1017–409
B1017–413
B1017–414
B1017–416
B1017–423
B1017–412
B1017–419
B1017–420
B1027–101
E, ES, FR,
PL, PT, RU
E, ES, FR,
PL, PT
E, ES, FR,
PL, PT
E, ES, FR,
PT, RU
E, ES, FR,
PT, RU
E ,ES, FR,
PT, RU
E, ES,
FR, PT
E, ES, FR,
PL, PT
E, ES,
FR, PT
E, ES,
FR, PT
DE, E, ES, FR, IT,
GR, NO, PL, PT, TR
µg/ml
µg/mL
µg/mL
µg/mL
µg/ml
µg/mL
µg/mL
µg/mL
µg/mL
µg/ml
µg/ml
Panel Definitions
Abbr.
8 – 32
16 – 32
16 – 32
16 – 32
16 – 32
16 – 32
16 – 32
4 – 32
4 – 32
8 – 32
–
Ak
8/4 – 16/8
8/4 – 16/8
–
–
–
–
8/4 – 16/8
–
8/4 – 16/8
8/4 – 16/8
–
Aug
2 – 16
8 – 16
8 – 16
8 – 16
8 – 16
8 – 16
8 – 16
2 – 16
2 – 16
2 – 16
–
Am
8/4 – 16/8
8/4 – 16/8
8/4 – 16/8
8/4 – 16/8
8/4 – 16/8
8/4 – 16/8
8/4 – 16/8
8/4 – 16/8
4/2 – 16/8
4/2 – 16/8
–
A/S
–
–
8 – 16
4 – 16
4 – 16
4 – 16
4 – 16
4 – 16
2 – 16
4 – 16
0.5 – 64
Azt
8 – 16
8 – 16
−
8 – 16
8 – 16
8 – 16
2 –4
2 – 16
2 – 16
2 – 16
–
Cfz
8 – 16
4 – 16
8 – 16
4 – 16
4 – 16
4 – 16
8 – 16
2 – 16
2 – 16
2 – 16
1– 32
Cpe
2, 8 – 321
2, 8 – 321
2, 8 – 321
2, 8 – 321
2, 8 – 321
2, 8 – 321
2, 8 – 321
2, 8 – 321
2 – 32
2 – 321
0.5 – 1281
Cft
0.5/4, 4/4
0.5/4, 4/4
0.5/4, 4/4
0.5/4, 4/4
0.5/4, 4/4
0.5/4, 4/4
0.5/4, 4/4
0.5/4, 4/4
–
0.5/4, 4/4
0.12/4 – 16/4
Cft/CA
–
–
16 – 32
–
–
–
–
16 – 32
–
–
1– 32
Ctn
–
–
–
8 – 16
8 – 16
8 – 16
–
8 – 16
2 – 16
4 – 16
2 – 32
Cfx
–
–
–
–
–
–
–
−
–
–
0.5 – 64
Cpd
1, 4 – 161
1, 4 – 161
1, 4 – 161
1, 4 – 161
1, 4 – 161
1, 4 – 161
1, 4 – 161
1– 161
2 – 16
1, 4 – 161
0.5 – 1281
Caz
0.25/4, 2/4
0.25/4, 2/4
0.25/4, 2/4
0.25/4, 2/4
0.25/4, 2/4
0.25/4, 2/4
0.25/4, 2/4
0.25/4, 2/4
–
0.25/4, 2/4
0.12/4 – 16/4
Caz/CA
4 – 8, 32
8 – 32
8, 32
1– 2, 8, 32
1 – 2, 8, 32
8, 32
1-2, 8, 32
4 – 32
1– 2, 8, 32
1– 2, 8, 32
1– 64
Cax
4 – 16
4 – 16
4 – 16
–
4 – 16
4 – 16
4 – 16
4 – 16
4 – 16
4 – 16
–
Crm
8 – 16
–
8 – 16
–
–
–
8 – 16
8 – 16
8 – 16
8 – 16
–
Cf
–
–
–
–
–
–
–
8 – 16
–
–
–
C
1– 2
1– 4
1– 2
1– 2
1– 2
1– 2
1– 2
0.5 – 2
0.5 – 4
0.5 – 2
–
Cp
Dor
−
−
–
0.5 – 2
–
0.5 – 2
–
–
0.5 – 2
–
–
–
2 –4
1– 4
1– 4
1– 4
1– 4
0.5 – 1
1– 4
0.5 – 4
0.5 – 4
–
Etp
–
–
–
–
–
–
–
−
–
–
–
ESβL
Gat
–
–
–
–
–
–
–
−
–
–
–
1– 8
4– 8
4 –8
4 –8
4 –8
4 –8
2 –8
1– 8
1– 8
1– 8
–
Gm
4 –8
1– 8
1– 8
–
1– 8
–
1 –8
1– 8
1– 8
1– 8
0.5 – 16
Imp
2 –4
2 –4
2 –4
–
2 –4
2 –4
2 –4
1– 4
0.5 – 4
1– 4
–
Lvx
–
1– 8
1– 8
1– 8
1– 8
1– 8
–
1– 8
1– 8
1– 8
0.5 – 16
Mer
Mxf
–
2 –4
–
–
–
–
–
−
–
2 –4
–
32 – 64
32 – 64
32 – 64
32 – 64
32 – 64
32 – 64
32 – 64
32 – 64
32 – 64
32 – 64
–
Fd
4 –8
–
–
–
–
–
–
−
–
–
–
Nxn
–
–
16 – 64
16, 64
–
–
–
16 – 64
–
16 – 64
16 – 64
Pi
8 – 64
16, 64
16, 64
16 – 64
16, 64
16, 64
16 – 64
8 – 64
8 – 64
8 – 64
–
P/T
4 –8
4 –8
4 –8
–
–
4 –8
4 –8
4 –8
2– 8
2 –8
–
Te
16, 64
16, 64
–
–
–
–
16, 64
8 – 64
–
–
–
Tim
–
–
2 –4
1– 4
2 –4
1– 4
–
1– 4
1– 4
1– 4
–
Tgc
2 –8
4 –8
4 –8
1– 8
4 –8
4 –8
4 –8
1– 8
1– 8
2 –8
–
To
–
–
–
–
–
–
8
–
–
–
–
T
0.5/9.5 –
2/38
–
T/S
29
13
0.5/9.5,
2/38
2/38
2/38
2/38
2/38
2/38
2/38
2/38
0.5/9.5 –
2/38
22
23
24
21
22
23
26
28
26
Neg Combo: Provides gramnegative identification and
susceptibility results on one
panel. Drug selection provides
both Enterobacteriaceae
and Non-Enterobacteriaceae
coverage, as well
as systemic reporting.
Neg BP (Breakpoint) Combo:
Provides gram-negative
identification and susceptibility
results on one panel. Drug
selection provides both
Enterobacteriaceae and NonEnterobacteriaceae coverage,
as well as urine and systemic
reporting. Panel contains shorter
dilutions around the breakpoints,
allowing for a broader
drug menu.
Neg/Urine Combo: Provides
gram-negative identification
and susceptibility results on
one panel. Drug selection
provides both Enterobacteriaceae
and Non-Enterobacteriaceae
coverage, as well as urine and
systemic reporting.
Neg MIC: Provides gram-negative
susceptibility results only and
longer dilution schemes for
better detection of emerging
resistance. Drug selection
provides both Enterobacteriaceae
and Non-Enterobacteriaceae
coverage, as well as urine and
systemic reporting.
ESβL plus: Provides confirmation
and susceptibility testing
of ESβL-producing E. coli, K.
pneumoniae, K. oxytoca,
and P. mirabilis.
Legend:
DE – German
E – English
ES – Spanish
FR – French
GR – Greek
IT – Italian
NO – Norwegian
PL – Polish
PT – Portuguese
RU – Russian
TR – Turkish
Stay ahead of emerging resistance —
the trusted way.
For more than 30 years, MicroScan Systems
have been exclusively focused on ID/AST testing,
offering unmatched experience, expertise, and
technical support to help guide physicians
and improve patient care.
MicroScan Dried Conventional Gram Negative
Panels continue a tradition of quality and
innovation. They are designed to help keep your
laboratory staff at the forefront of identification
and susceptibility testing and are compatible with
all MicroScan instruments.
› Provide clinically relevant identification from
an extensive database of Gram-negative
microorganisms
Versatility for your unique
testing needs
Experience flexibility and choice through dynamic
MicroScan menu options designed to streamline
testing and help boost your efficiency.
›M
anage changing formulary needs with a broad
antimicrobic menu and more than 95 MicroScan
panel choices (available globally)
› Select ID-only, AST-only, and ID/AST combination
panels for workflow flexibility
› Utilize a one-panel format for all MicroScan
microbiology instruments for simplified testing
procedures and streamlined workflow
› Confirm or screen for extended-spectrum
beta-lactamases (ESβL) with routine panels
› Perform and interpret tests manually or on any
MicroScan instrumentation
FIRST-TIME ACCURACY
The MicroScan system uses a growth-based, non-ID-dependent direct testing method, which allows for better detection of
emerging resistance. The system does not rely on historical data: It provides a real-time advantage for accuracy and uses
direct MIC* technology to detect emerging and low-level resistance. This means fewer confirmatory tests are needed,
providing you with accurate results the first time. This functionality aligns with most CLSI guidelines to improve detection
of resistance mechanisms without additional confirmation tests.
*Minimum inhibitory concentration
eckman Coulter, the stylized logo and MicroScan are trademarks of Beckman Coulter, Inc. and are
B
registered with the USPTO. Lab Forward is a trademark of Beckman Coulter, Inc.
All other trademarks are the property of their respective owners.
or Beckman Coulter’s worldwide office locations and phone numbers, please visit
F
www.beckmancoulter.com/contact
BR-18595A B2014-20154
© 2015 Beckman Coulter, Inc. www.beckmancoulter.com